Fresenius Medical Care AG & Co. KGaA (FME) AI Stock Analysis

• Market Cap: €12.46B
• Dividend Yield: 2.83%
• Average Volume (3M): 577.42K
• Price to Earnings (P/E): 23.2
• Beta (1Y): 0.75
• Revenue Growth: -0.60%
• EPS Growth: 7.80%
• Country: DE
• Employees: 111,513
• Sector: Healthcare
• Sector Strength: 65
• Industry: Healthcare Providers & Services
• EPS (TTM): 1.83
• Shares Outstanding: 293,413,450
• 10 Day Avg. Volume: 514,764
• 30 Day Avg. Volume: 577,422
• PEG Ratio: 2.97
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.72
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €45.54
• Price Target Upside: 7.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 14

Fresenius Medical Care's stock is moderately positioned with stable financials and a balanced capital structure. However, the lack of strong growth indicators and bearish technical signals limit its current performance. The valuation suggests a reasonable entry point, supported by a solid dividend yield, but overall momentum is lacking due to neutral market conditions.

Positive Factors

Cost Savings

FME25 savings are running ahead of plan and expect €205m for the full year, which supports sequential margin improvement.

Financial Performance

Fresenius Medical Care beat expectations on sales and EBIT, driven by positive price and volume in Care Enablement and stable US treatment volumes.

Negative Factors

Market Challenges

There is continued caution on the dialysis market, which is seen as structurally challenged and at risk of reimbursement changes.

Regulatory Impact

Premium subsidies for ACA exchanges are likely to end, which could negatively impact the coverage for some patients and slightly affect EBIT.

Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

How the Company Makes Money

Fresenius Medical Care AG & Co. KGaA generates revenue primarily through its healthcare services and products. The company earns a significant portion of its income by providing dialysis services to patients, which includes both in-center hemodialysis treatments and home dialysis options. These services are often reimbursed through government health programs and private insurance. Additionally, FME produces and sells dialysis-related products, such as machines and consumables, to healthcare facilities and clinics globally. Strategic partnerships and agreements with healthcare providers and payers also play a crucial role in expanding its market reach and revenue generation. The company's integrated approach, combining services and products, allows it to capture value across the entire dialysis treatment chain.

Fresenius Medical Care AG & Co. KGaA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
19.34B	19.45B	19.40B	17.62B	17.86B
	Gross Profit
4.76B	4.93B	5.31B	5.08B	5.54B
	EBIT
1.39B	1.37B	-258.36M	301.32M	529.00M
	EBITDA
3.21B	2.93B	3.22B	3.42B	3.83B
	Net Income Common Stockholders
537.91M	499.00M	673.40M	969.31M	1.16B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.45B	1.54B	1.44B	1.62B	1.24B
	Total Assets
33.57B	33.93B	35.75B	34.37B	31.69B
	Total Debt
10.98B	12.05B	13.21B	13.32B	12.38B
	Net Debt
9.83B	10.65B	11.94B	11.84B	11.30B
	Total Liabilities
17.80B	19.10B	20.30B	20.39B	19.36B
	Stockholders Equity
14.58B	13.62B	15.45B	13.98B	12.33B
Cash Flow		Free Cash Flow
1.69B	1.94B	756.00M	806.00M	2.15B
	Operating Cash Flow
2.39B	2.63B	2.17B	2.49B	4.23B
	Investing Cash Flow
-84.94M	-544.23M	-734.73M	-1.20B	-1.33B
	Financing Cash Flow
-2.57B	-1.86B	-1.62B	-1.02B	-2.66B

Fresenius Medical Care AG & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 42.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Negative. The current price of 42.45 is below the 20-day moving average (MA) of 43.71, below the 50-day MA of 44.38, and above the 200-day MA of 40.92, indicating a neutral trend. The MACD of -0.68 indicates Positive momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 46.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:FME.

Fresenius Medical Care AG & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FME	60 Neutral	€12.46B	23.15	3.82%	2.83%	-0.60%	7.80%
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%